| Literature DB >> 26409799 |
Talat Elkersh, Mohammed A Marie, Yazeed A Al-Sheikh, Ahmad AlBloushy, Mohammad H Al-Agamy1.
Abstract
BACKGROUND AND OBJECTIVES: Commensal neonatal fecal flora constitute a reservoir of antibiotic resistance. The aim of this study was to characterize the prevalence of fecal carriage of extended spectrum beta lactamases (ESBLs) and carbapenemase producing gram-negative bacteria among 150 neonates who were born in two hospitals in central Saudi Arabia. PATIENTS AND METHODS: From June 2012 to January 2013, 150 healthy neonates.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26409799 PMCID: PMC6074465 DOI: 10.5144/0256-4947.2015.240
Source DB: PubMed Journal: Ann Saudi Med ISSN: 0256-4947 Impact factor: 1.526
Distribution of different gram-negative bacteria by clinical characteristics of subjects.
| Characteristics | Number of neonates | Recovered gram negative bacteria (n=188) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Others | ||||||||||
| n/% | n/% | n/% | n/% | |||||||
|
| ||||||||||
| 1 | 45 | 43/95.6 | .03 | 6/13.3 | .554 | 1/2.2 | .021 | 8/17.8 | .450 | |
| 2 | 47 | 39/83 | 11/23.4 | 5/10.6 | 8/17 | |||||
| 3 | 41 | 36/87.8 | 4/9.7 | 4/9.7 | 1/2.4 | |||||
| 4–7 | 17 | 12/70.6 | 2/11.7 | 4/23.5 | 4/23.5 | |||||
|
| ||||||||||
| Vaginal | 78 | 70/89.74 | .249 | 10/12.8 | .374 | 5/6.4 | .200 | 9/11.5 | .366 | |
| Cesarean | 72 | 60/83.3 | 13/18.1 | 9/12.5 | 12/16.6 | |||||
|
| ||||||||||
| <2 | 4 | 4/100 | .0001 | 1/25 | .848 | 0/0 | .002 | 0/0 | .917 | |
| 2–3 | 65 | 58/89.2 | 11/16.9 | 3/4.6 | 8/12.3 | |||||
| 3–4 | 72 | 62/86.1 | 7/9.7 | 6/8.3 | 13/18.1 | |||||
| >4 | 9 | 6/66.6 | 4/44.4 | 5/55.5 | 0/0 | |||||
|
| ||||||||||
| Breast | 27 | 26/96.3 | .239 | 8/29.6 | .075 | 3/11.1 | .904 | 0/0 | .02 | |
| Bottle | 83 | 71/85.5 | 10/12.1 | 7/8.4 | 17/20.5 | |||||
| Mixed | 40 | 33/82.5 | 5/12.5 | 4/10 | 4/10 | |||||
A baumannii (n=9), E cloacae (n=5), E aerogenes (n=4) and M morganii (n=3).
Chi - Square Linear trend
Resistance patterns and MIC50/90 of 188 gram negative rods isolated from neonate’s stool.
| Antibiotic | Antibiotic susceptibility pattern | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R | MIC | R | MIC | R | MIC | R | MIC | R | MIC | R | MIC | R | MIC | ||||||||
| No | % | No | % | No | % | No | % | No | % | No | % | No | % | ||||||||
|
| |||||||||||||||||||||
| AMP | 73 | 56.1 | 16/≥32 | 23 | 100 | 32/≥32 | 3 | 60 | 32/≥32 | 3 | 75 | 8/≥32 | 3 | 100 | 32/≥32 | 14 | 100 | 32/≥32 | 9 | 100 | 16/≥32 |
| AMC | 53 | 40.7 | 16/≥32 | 1 | 5 | 16/≥32 | 3 | 60 | 16/≥32 | 3 | 75 | 16/≥32 | 3 | 100 | 32/≥32 | 14 | 100 | 16/≥32 | 7 | 77.7 | 16/≥32 |
| TZP | 14 | 1 | 32/≥128 | 1 | 5 | 128/≥128 | 3 | 60 | 128/≥128 | 1 | 25 | 128/≥128 | 0 | 0 | 4/≥4 | 2 | 14 | 128/≥128 | 6 | 66.7 | 64/≥128 |
| CXM | 39 | 3 | 16/≥64 | 1 | 5 | 64/≥64 | 4 | 80 | 64/≥64 | 1 | 25 | 64/≥64 | 3 | 100 | 64/≥64 | 14 | 100 | 16/≥64 | 9 | 100 | 32/≥64 |
| FOX | 55 | 4 | 32/≥64 | 0 | 0 | 4/≥4 | 4 | 80 | 4/≥4 | 1 | 25 | 64/≥64 | 1 | 33.3 | 16/≥16 | 14 | 100 | 64/≥64 | 9 | 100 | 64/≥64 |
| CTX | 18 | 1 | 16/≥64 | 1 | 5 | 64/≥64 | 3 | 60 | 64/≥64 | 1 | 25 | 64/≥64 | 1 | 33.3 | 16/≥16 | 14 | 100 | 16/≥64 | 9 | 100 | 32/≥64 |
| CAZ | 17 | 13 | 16/≥64 | 1 | 5 | 16/≥16 | 3 | 60 | 16/≥16 | 1 | 25 | 64/≥64 | 1 | 33.3 | 16/≥16 | 1 | 7 | 16/≥16 | 0 | 0 | 16/≥16 |
| FEP | 8 | 6 | 8/≥64 | 1 | 5 | 4/≥4 | 3 | 60 | 4/≥4 | 0 | 0 | 1/≥2 | 0 | 0 | 2/≥2 | 0 | 0 | 2/≥16 | 0 | 0 | 1/≥16 |
| MEM | 0 | 0 | 0.25/≥0.25 | 0 | 0 | 0.25/≥0.25 | 3 | 60 | 2/2 | 0 | 0 | 0.25/≥0.25 | 0 | 0 | 0.25/≥0.25 | 0 | 0 | 0.25/≥0.25 | 0 | 0 | 0.25/≥0.25 |
| AMK | 0 | 0 | 2/≥4 | 0 | 0 | 2/≥4 | 3 | 60 | 2/≥4 | 0 | 0 | 2/≥2 | 0 | 0 | 2/≥2 | 0 | 0 | 2/≥2 | 0 | 0 | 2/≥2 |
| GEN | 8 | 6 | 16/≥16 | 1 | 5 | 16/≥16 | 3 | 60 | 16/≥16 | 0 | 0 | 1/≥1 | 0 | 0 | 1/≥1 | 1 | 7 | 16/≥16 | 0 | 0 | 16/≥16 |
| CIP | 2 | 1.5 | 4/≥4 | 0 | 0 | 0.25/≥0.25 | 3 | 60 | 0.25/≥0.25 | 0 | 0 | 0.25/≥0.25 | 0 | 0 | 0.25/≥0.25 | 0 | 0 | 0.25/≥0.25 | 0 | 0 | 0.25/≥0.25 |
| NIT | 65 | 50 | 64/≥512 | 20 | 87 | 64/≥128 | 5 | 100 | 64/≥128 | 4 | 100 | 64/≥128 | 3 | 100 | 128/≥128 | 14 | 100 | 16/≥512 | 9 | 100 | 16/≥512 |
| SXT | 14 | 11 | 80/≥320 | 1 | 5 | 320/≥320 | 5 | 100 | 320/≥320 | 0 | 0 | 20/≥20 | 0 | 0 | 20/≥20 | 12 | 86 | 80/≥160 | 3 | 33.3 | 80/≥160 |
AMP, ampicillin; AMC, amoxicillin-clavulanic acid; TZP, piperacillin-tazobactam; CAZ, ceftazidime; FEP, cefepime; CXM, cefuroxime; FOX, cefoxitin; CTX, cefotaxime; GEN, gentamicin; AMK, amikacin; CIP, ciprofloxacin; MEM, meropenem; NIT, nitrofurantoin; SXT, sulfamethoxazole-trimethoprim; R=Resistant.
Resistance patterns of ESBL-positive and ESBL-negative strains isolated from neonates.
| Antibiotics | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ESBL positive (n=22/130; 17%) | ESBL negative (n=108/130; 83%) | ESBL positive (n=1/23; 4%) | ESBL negative (n=22/23; 95.6%) | ESBL positive (n=3/5; 60%) | ESBL negative (n=2/5; 40%) | ESBL positive (n=1/4; 25%) | ESBL negative (n=3/4; 75%) | ESBL positive (n=1/3; 33.3%) | ESBL negative (n=2/3; 66.7%) | |
|
| ||||||||||
| AMP | 22 (100) | 69(63.9) | 1 (100) | 22(100) | 3 (100) | 0 (0) | 1(100) | 2(67.7) | 1(100) | 2 (100) |
| AMC | 21(95.5) | 32(29.6) | 1 (100) | 0 (0) | 3 (100) | 0 (0) | 1(100) | 2 (67.7) | 1(100) | 2 (100) |
| TZP | 10(45) | 4 (3.7) | 1 (100) | 0 (0) | 3 (100) | 0 (0) | 1(100) | 0 (0) | 0/0 | 0 (0) |
| CXM | 22(100) | 17(15.7) | 1 (100) | 0 (0) | 3 (100) | 1 (50) | 1(100) | 0.0(0) | 1(100) | 2 (100) |
| FOX | 21(95.5) | 34(31.5) | 0 (0) | 0 (0) | 3.0(100) | 1 (50) | 1(100) | 3 (100) | 1(100) | 0 (0) |
| CTX | 18(82) | 0 (0) | 1 (100) | 0 (0) | 3 (100) | 0 (0) | 1(100) | 0 (0) | 1(100) | 0 (0) |
| CAZ | 17(72) | 0 (0) | 1 (100) | 0 (0) | 3 (100) | 0 (0) | 1(100) | 0 (0) | 1(100) | 0 (0) |
| FEP | 8 (36) | 0 (0) | 1 (100) | 0 (0) | 3 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| MEM | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| AMK | 0 (0) | 0 (0) | 1 (100) | 0 (0) | 3 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| GEN | 3 (13.6) | 5 (5) | 1 (100) | 0 (0) | 3 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| CIP | 2 (9.1) | 0 (0) | 0 (0) | 0 (0) | 3 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| NIT | 9(40.9) | 56(51.8) | 1 (100) | 8 (36.4) | 3 (100) | 2 (100) | 1 (100) | 3 (100) | 1(100) 2 | (100) |
| SXT | 7(31.8) | 7.0(6.5) | 1 (100) | 0 (0) | 3 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
AMP, ampicillin; AMC, amoxicillin-clavulanic acid; TZP, piperacillin-tazobactam; CAZ, ceftazidime; FEP, cefepime; CXM, cefuroxime; FOX, cefoxitin; CTX, cefotaxime; GEN, gentamicin; AMK, Amikacin; CIP, ciprofloxacin; MEM, meropenem; NIT, nitrofurantoin; SXT, sulfamethoxazole-trimethoprim.